BOSTON SCIENTIFIC CORP BSX
BOSTON SCIENTIFIC CORP (BSX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.04% (safety: no dividend).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-31 | Argus Research | Hold (down) |
| 2026-07-30 | UBS | Buy (main) |
| 2026-07-30 | Citigroup | Buy (main) |
| 2026-07-30 | RBC Capital | Outperform (main) |
| 2026-07-30 | TD Cowen | Buy (main) |
| 2026-07-30 | Canaccord Genuity | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.077 |
| Retained earnings / assets | 0.128 |
| EBIT / assets | 0.083 |
| Equity / liabilities | 1.275 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BSX | BOSTON SCIENTIFIC CORP | 4/9 | 2.81 | — | +19.9% |
| BDX | BECTON DICKINSON & CO | 6/9 | 2.29 | 25.6 | +8.2% |
| MMM | 3M CO | 5/9 | 5.46 | 26.3 | +1.5% |
| SYK | STRYKER CORP | 4/9 | 3.96 | 39.3 | +11.2% |
| MDLN | Medline Inc. | 6/9 | 2.84 | 44.1 | +11.5% |
| BAX | BAXTER INTERNATIONAL INC | 5/9 | 3.86 | — | +5.7% |
| SOLV | Solventum Corp | 6/9 | 2.34 | 8.9 | +0.9% |
About BOSTON SCIENTIFIC CORP
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
FAQ
Is BSX financially healthy?
BOSTON SCIENTIFIC CORP's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does BSX pay a dividend, and is it safe?
Yes. BOSTON SCIENTIFIC CORP pays a dividend yielding about 0.04% with a None payout ratio, rated “no dividend” for safety.
Is BSX overvalued or undervalued?
BOSTON SCIENTIFIC CORP trades at about 26.5× trailing earnings — below its 10-year norm (10-year range 12.6×–349.5×, median 62.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for BSX?
The average Wall-Street price target for BOSTON SCIENTIFIC CORP is $62.69, about 21.9% above the recent price, from 29 analysts (consensus: buy).
Is BSX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BOSTON SCIENTIFIC CORP: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a dividend yield of 0.04%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.